Bausch + Lomb (NYSE:BLCO – Get Rating) had its price objective boosted by Barclays from $17.00 to $18.00 in a report published on Friday, The Fly reports. A number of other research analysts have also weighed in on BLCO. Morgan Stanley raised their price objective on Bausch + Lomb from $18.00 to $20.00 and gave […]
Bausch + Lomb (NYSE:BLCO – Get Rating) had its price target boosted by Barclays from $17.00 to $18.00 in a research note released on Friday, The Fly reports. Several other analysts have also issued reports on the stock. HC Wainwright reiterated a buy rating and issued a $21.00 target price on shares of Bausch + […]
Bausch + Lomb (NYSE:BLCO – Get Rating) and Innovative Eyewear (NASDAQ:LUCY – Get Rating) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings. Insider and Institutional Ownership 12.4% of Bausch + Lomb […]
Bausch + Lomb Co. (NYSE:BLCO – Get Rating) saw a large decline in short interest in the month of March. As of March 15th, there was short interest totalling 7,010,000 shares, a decline of 5.7% from the February 28th total of 7,430,000 shares. Based on an average trading volume of 382,700 shares, the days-to-cover ratio […]
Shares of Bausch + Lomb Co. (NYSE:BLCO – Get Rating) have earned an average rating of “Moderate Buy” from the sixteen research firms that are covering the company, MarketBeat.com reports. Five equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The average 1-year […]